Tami Crabtree

Advantest (Singapore)

Papers

1

Total Citations

14

H-Index

1

About

Tami Crabtree is a leading clinical researcher in radiation oncology, with a focused expertise in prostate stereotactic body radiotherapy (SBRT). Her most impactful work centers on establishing the long-term efficacy and safety of high-dose, “HDR-like” prostate SBRT regimens. As a key contributor to a landmark, multi-institutional clinical trial involving 18 institutions and 259 patients, Crabtree helped produce one of the few mature 10-year outcome datasets in the field. This study, published in 2022, reported PSA control rates and toxicity profiles over a median follow-up of 5.5 years, providing critical evidence that supports SBRT as a definitive treatment for low- and intermediate-risk prostate cancer. With 14 citations already, this work is shaping modern practice guidelines. Crabtree’s contributions are notable for bridging the gap between shorter-term reports and the long-term data essential for clinical decision-making, reinforcing her role as a vital figure in advancing non-invasive cancer therapies. Her research continues to influence how radiation oncologists optimize dose delivery for durable disease control.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
High Dose “HDR-Like” Prostate SBRT: PSA 10-Year Results From a Mature, Multi-Institutional Clinical Trial
14 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Advantest (Singapore)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago